New injection aims to make artery plaques less dangerous

NCT ID NCT06788431

Recruiting now Disease control Sponsor: ImmuneOnco Biopharmaceuticals (Shanghai) Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests an injectable drug called IMC-001 in 18 people who recently had a heart attack or unstable angina. The goal is to see if it can safely stabilize fatty plaques in the arteries, making them less likely to cause future heart problems. Participants are randomly assigned to receive either the drug or a placebo, alongside standard care, and plaque changes are measured with a CT scan after 6 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IMC-001 (an injectable drug)
What this could lead to: If it works, this could point toward a new way to stabilize artery plaques and reduce the risk of future heart attacks in people with acute coronary syndrome.
What could go wrong: This is a very early, small trial with only 18 participants, so results may not apply widely. The drug is unproven in humans for this use, and safety is the main focus.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATHEROSCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute coronary syndrome atherosclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATHEROSCLEROSIS

Contacts and locations

Locations

Renji Hospital,Shanghai
RECRUITING

Shanghai, Shanghai Municipality, China
The First Affiliated Hospital of Nanyang Medical College
RECRUITING

Nanyang, Henan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.